Patents by Inventor Samuel Singer

Samuel Singer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11968809
    Abstract: A system and a method of providing electromagnetic compatibility (EMC) protection. A removable component is inserted into an end product. The removable component includes a retractable EMC protection apparatus. In response to the insertion of the removable component a shape memory alloy on the EMC protection apparatus is heated to a temperature above the activation temperature of the shape memory alloy. The shape memory alloy then changes from a first shape to a second shape in response to the heating. In response to the change in the shape of the shape memory alloy an EMC protection component of the EMC protection apparatus is inserted into an enclosure opening of the removable component.
    Type: Grant
    Filed: July 21, 2023
    Date of Patent: April 23, 2024
    Assignee: International Business Machines Corporation
    Inventors: John S. Werner, Noah Singer, Samuel R. Connor
  • Patent number: 11921116
    Abstract: The present disclosure relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. Accordingly, in certain non-limiting embodiments, the present disclosure provides for methods, compositions and kits for a companion diagnostic for CDK4 inhibitors, and in particular, for the use of the colocalization of Enigma and CDH18 biomarkers to foci within the cancer for determining whether the cancer can be successfully treated by CDK4 inhibition.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: March 5, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Mary Elizabeth Dooley, Marta Kovatcheva, Samuel Singer, William D. Tap, Aimee Crago, Andrew Koff
  • Publication number: 20190310259
    Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. Accordingly, in certain non-limiting embodiments, the present invention provides for methods, compositions and kits for a companion diagnostic for CDK4 inhibitors, and in particular, for the use of the colocalization of Enigma and CDH18 biomarkers to foci within the cancer for determining whether the cancer can be successfully treated by CDK4 inhibition.
    Type: Application
    Filed: March 9, 2017
    Publication date: October 10, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Mary Elizabeth KLEIN, Marta KOVATCHEVA, Samuel SINGER, William D. TAP, Aimee CRAGO, Andrew KOFF
  • Patent number: 9889135
    Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: February 13, 2018
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Andrew Koff, Aimee Crago, David Liu, Marta Kovatcheva, Samuel Singer, Gary K. Schwartz, Mark A. Dickson, Mary Elizabeth Klein
  • Publication number: 20160222131
    Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer cells expressing ATRX prior to treatment are more likely to undergo cellular senescence in response to treatment with a CDK4 inhibitor. It is also based, at least in part, on the discovery that ATRX is phosphorylated in cancer cells that are not as responsive to CDK4 inhibitor therapy. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of ATRX expression as a biomarker for determining the likelihood that a cancer can be successfully and/or unsuccessfully treated by CDK4 inhibition.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 4, 2016
    Inventors: Andrew Koff, Marta Kovatcheva, Samuel Singer, John Petrini, Mary Elizabeth Klein
  • Publication number: 20160030433
    Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Andrew Koff, Aimee Crago, David Liu, Marta Kovatcheva, Samuel Singer, Gary K. Schwartz, Mark A. Dickson, Mary Elizabeth Klein
  • Patent number: 8405392
    Abstract: Techniques for corrected nuclear magnetic resonance (NMR) data include applying a presaturation radio frequency (RF) magnetic field different from a fat molecule resonance for a particular time to a target tissue; and applying a first measurement RF magnetic field within a first time after the particular time. Correction nuclear magnetic resonance (NMR) data from the target tissue is determined based on first NMR data received in response to applying the first measurement RF magnetic field. In some embodiments, a second measurement RF magnetic field is also applied in a second time different from both the particular time and the first time. Corrected NMR data is determined by subtracting the correction NMR data from second NMR data received in response to applying the second measurement RF magnetic field. Among other applications, these techniques allow distinguishing either fat or proteins in edemas, or both, from proteins in other tissues.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: March 26, 2013
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Jin-Hong Chen, Samuel Singer
  • Publication number: 20100156413
    Abstract: Techniques for corrected nuclear magnetic resonance (NMR) data include applying a presaturation radio frequency (RF) magnetic field different from a fat molecule resonance for a particular time to a target tissue; and applying a first measurement RF magnetic field within a first time after the particular time. Correction nuclear magnetic resonance (NMR) data from the target tissue is determined based on first NMR data received in response to applying the first measurement RF magnetic field. In some embodiments, a second measurement RF magnetic field is also applied in a second time different from both the particular time and the first time. Corrected NMR data is determined by subtracting the correction NMR data from second NMR data received in response to applying the second measurement RF magnetic field. Among other applications, these techniques allow distinguishing either fat or proteins in edemas, or both, from proteins in other tissues.
    Type: Application
    Filed: December 21, 2009
    Publication date: June 24, 2010
    Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Jin-Hong Chen, Samuel Singer
  • Patent number: 7635708
    Abstract: The present invention is based on the finding that activation of PPAR? plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR? agonists, such as thiazolidinedione ligands (TZDs), is effective both in vitro and in vivo at inhibiting the proliferation of such cells.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: December 22, 2009
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Elisabetta Mueller, Pasha Sarraf, Soner Altiok, Peter Tontonoz, Samuel Singer
  • Publication number: 20030144330
    Abstract: The present invention is based on the finding that activation of PPAR&ggr; plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR&ggr; agonists, such as thiazolidinedione ligands (TZDs), is effective both in vitro and in vivo at inhibiting the proiferation of such cells.
    Type: Application
    Filed: December 19, 2002
    Publication date: July 31, 2003
    Inventors: Bruce M. Spiegelman, Elisabetta Mueller, Pasha Sarraf, Soner Altiok, Peter Tontonoz, Samuel Singer
  • Patent number: 6552055
    Abstract: The present invention is based on the finding that activation of PPAR&ggr; plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR&ggr; agonists, such as thiazolidinedione ligands (TZDs), is effective both in vitro and in vivo at inhibiting the proiferation of such cells.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: April 22, 2003
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Elisabetta Mueller, Pasha Sarraf, Soner Altiok, Peter Tontonoz, Samuel Singer
  • Patent number: 6353490
    Abstract: The bandwidth of a two-way broadband signal transmission system is expanded by frequency stacking shared band signals. The up conversion (stacking) and down conversion (destacking) systems utilize matched filters, preferably in a multiplexer configuration, which are directly connected, without a combiner, to output the stacked frequency signal in the case of the up conversion system, and without a splitter to separate the frequency stacked signals in the down conversion system. A single base local oscillator signal is used to generate all of the local oscillator signals needed in the system for up and down conversion.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: March 5, 2002
    Assignee: Quintech, Inc.
    Inventors: Samuel Singer, Harry Krasnikoff, Maximo V. Morales
  • Patent number: 6208219
    Abstract: Broadband RF circuits in which multiple circuit elements are interconnected by microstrips arranged in regular patterns on printed circuit boards have the microstrips laid out in randomly meandering paths such that adjacent paths are non-parallel and non-symmetrical about a common axis, to increase the isolation between adjacent signal paths in broadband splitters, combiners, routers, switching systems and control systems operating up to the GHz frequency range.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: March 27, 2001
    Inventor: Samuel Singer
  • Patent number: 5558627
    Abstract: An orthopaedic brace for a joint includes a support mechanism attached to limb members on either side of the joint for providing support to the joint and for permitting a predetermined range of movement of the joint. The support mechanism defines a void space substantially surrounding the joint between the support mechanism and the joint. An inflatable air bag that preferably includes several air cells substantially surrounds the joint in the void space. At least one sensor attached to the support mechanism provides a trigger signal in response to a predetermined, potentially injurious condition, such as a severe force, stress, strain or acceleration. An inflation mechanism operatively connected to the air bag and the sensor inflates the air bag in response to the trigger signal, thereby providing additional support to the joint before the joint is injured.
    Type: Grant
    Filed: December 6, 1993
    Date of Patent: September 24, 1996
    Inventors: Samuel Singer, Jeffrey A. Fried
  • Patent number: 5481073
    Abstract: The basic element of a modular, bidirectional broadband programmable switch system is a switch module having a thin rectangular housing with a single first connector preferably in the center of an elongated rear face and n second connectors equally spaced along the elongated front face. Broadband switches within the module selectively connect the single first connector with any one of the second connectors to provide an n.times.1 or 1.times.n switch. Up to n of the switch modules can be stacked side-by-side with an additional module extending transversely with its n second connectors connected to the first connectors on the stacked modules to provide an n.sup.2 .times.1 or 1.times.n.sup.2 switch. The first connectors on the additional modules of two such stacks can be connected to provide an n.sup.2.times.n.sup.2 switch.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: January 2, 1996
    Assignee: Quintech, Inc.
    Inventors: Samuel Singer, Francis J. DeSantis, Harry Krasnikoff
  • Patent number: 5422638
    Abstract: A conventional STOP/SLOW traffic control sign mounted on a pole is supported and remotely operated by a portable stand having a tubular support mounted on a foldable frame which also carries a remotely controlled drive assembly so that the sign can be operated at a safe distance even by a person with disabilities.
    Type: Grant
    Filed: February 24, 1994
    Date of Patent: June 6, 1995
    Assignee: Quintech, Inc.
    Inventors: Samuel Singer, Harry Krasnikoff, Richard E. Miller, Frank C. Elling
  • Patent number: 5267946
    Abstract: A knee brace has an adjustable rigid posterior strut with an arcuate member which extends through the popliteal space behind the knee joint and is made of two halves which can be extended or retracted axially or rotated with respect to one another. Terminal portions of the strut, to which supports secured to the leg and thigh are hinged, are adjustably secured by ball and socket connections to mounting members which in turn are adjustably attached to the arcuate member by stems which telescope into and rotate within bores in the ends of the two halves of the arcuate member. With these adjustments the components of the posterior strut can be locked in a myriad of configurations to accommodate for various sizes and deformities of protected joints.
    Type: Grant
    Filed: April 1, 1992
    Date of Patent: December 7, 1993
    Inventors: Samuel Singer, Jeffrey A. Fried
  • Patent number: 5133341
    Abstract: A knee brace has a rigid posterior strut behind the knee joint in the popliteal area with terminal portions adjacent, but spaced from the lateral and medial sides of the knee. A prophylactic embodiment of the invention has a lateral inferior rigid support member pivoted on the lateral terminal portion of the strut and secured to the leg, and a medial superior rigid support member pivoted on the medial terminal portion of the strut and secured to the thigh. Stiff anterior, generally triangular, cuff members each have one edge secured to one of the rigid support members and an opposite vertex detachably, pivotally secured to the opposite terminal portion of the strut. A functional brace in accordance with the invention has both lateral and medial rigid support members pivoted on the terminal portions on the posterior strut, additional stiff anterior generally triangular cuffs criss-crossing above and below the knee join and stiff posterior cuffs between the pairs of rigid support members.
    Type: Grant
    Filed: March 1, 1991
    Date of Patent: July 28, 1992
    Inventors: Samuel Singer, Jeffrey A. Fried
  • Patent number: 5045314
    Abstract: Nematodes are controlled in host animals by contacting the animal or its environment with a bacterial toxin produced by strains of Bacillus laterosporus, the toxin being capable of inhibiting nematode egg hatchability and/or larval development.
    Type: Grant
    Filed: November 14, 1989
    Date of Patent: September 3, 1991
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Leon W. Bone, Samuel Singer
  • Patent number: 5040760
    Abstract: A support for a keyboard for a computer resting on spaced apart feet on a narrow support surface includes two articulated elongated members which are spaced apart laterally the distance between the feet on the computer by cross-braces. The first end sections of the elongated members are placed on the support surface under the spaced apart feet of the computer to cantilever the middle sections and second end sections out over the edge of the support surface with the middle sections extending generally downward adjacent the edge of the support surface and the second end sections extending generally laterally outward from the middle sections to form spaced part supports for the keyboard.
    Type: Grant
    Filed: July 16, 1990
    Date of Patent: August 20, 1991
    Assignee: Andray Mining Company
    Inventor: Samuel Singer